BioArctic AB Stock price

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 07:59:53 2024-03-28 am EDT 5-day change 1st Jan Change
215.4 SEK -0.19% Intraday chart for BioArctic AB -8.81% -19.57%
Sales 2023 616M 57.52M Sales 2024 * 502M 46.92M Capitalization 19.02B 1.78B
Net income 2023 229M 21.38M Net income 2024 * 16M 1.49M EV / Sales 2023 37.4 x
Net cash position 2023 607M 56.65M Net cash position 2024 * 838M 78.22M EV / Sales 2024 * 36.2 x
P/E ratio 2023
103 x
P/E ratio 2024 *
1,083 x
Employees 88
Yield 2023 *
-
Yield 2024 *
-
Free-Float 44.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.19%
1 week-8.81%
Current month+0.47%
1 month-2.97%
3 months-21.96%
6 months-23.07%
Current year-19.57%
More quotes
1 week
209.20
Extreme 209.2
221.60
1 month
209.00
Extreme 209
245.40
Current year
191.50
Extreme 191.5
288.40
1 year
191.50
Extreme 191.5
392.00
3 years
66.70
Extreme 66.7
392.00
5 years
47.00
Extreme 47
392.00
10 years
20.40
Extreme 20.4
392.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 14-01-26
Founder 77 03-01-23
Founder 75 03-01-23
Members of the board TitleAgeSince
Chairman 70 16-12-31
Director/Board Member 58 23-05-31
Director/Board Member 56 -
More insiders
Date Price Change Volume
24-03-28 215.4 -0.19% 35,675
24-03-27 215.8 -1.55% 69,201
24-03-26 219.2 +1.95% 101,712
24-03-25 215 +0.66% 132,773
24-03-22 213.6 -9.57% 430,956

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT

More quotes
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
215.4 SEK
Average target price
366.2 SEK
Spread / Average Target
+70.01%
Consensus
  1. Stock
  2. Equities
  3. Stock BioArctic AB - Nasdaq Stockholm